Industry
Biotechnology
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
July 22, 2024 | 12:21 pm
Portfolio Pulse from Avi Kapoor
July 16, 2024 | 12:15 pm
Portfolio Pulse from Avi Kapoor
July 16, 2024 | 9:51 am
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 10:11 am
Portfolio Pulse from Avi Kapoor
June 03, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 11:53 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
February 07, 2024 | 12:32 pm
Portfolio Pulse from Benzinga Insights
February 07, 2024 | 10:13 am
Portfolio Pulse from Benzinga Insights
February 06, 2024 | 7:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.